AG Pecher: Abdelhadi Boulifa, Alexander Franzén, Prof. Dr. med. Gabriele Pecher, Dr. Martin Raftery, Clarissa Radecke (from left to right).
At the 4th Immuno-Oncology World Congress, the Kompetenzzentrum Immunonkologie und Translationale Zelltherapie (KITZ) headed by Professor Gabriele Pecher has received the prize for the best contribution “Next generation CD44v6-specific CAR-NK cells effective against solid tumors”.
The group of Professor Pecher develops innovative immunotherapeutics as "off-the-shelf products" from iPSC (induced pluripotent stem cells) for the treatment of malignant diseases. The work is funded by our BIH-SPARK program and the BMBF.
The 4th Immuno-Oncology World Congress (Immuno-Oncology2023) took place on December 4-5 in Frankfurt and focused on the latest developments and findings in immuno-oncology therapy as well as targeted therapy. The Congress examined treatments available on the market as well as treatments still in the development stage. In this context, the Congress welcomed Oncologists, Dermatologists, Immunologists, Surgical Oncologists, clinical scientists, industry leaders and other experts.
